Latest news on thumbs down for Nuplazid; Amylyx’s first ALS approval; Buyout buzz for troubled biotechs; Cannes Lions preview; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
It’s one conference after the other in June. Now that #BIO22 is behind us, we’re shifting gears to Zach Brennan’s upcoming events at #DIA22 and on-the-ground coverage from Cannes Lions by Beth Snyder Bulik and Nicole DeFeudis. If you’re taking a long weekend like us — we’re off Monday in observance of Juneteenth — I hope it’s just what you need.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,400+ biopharma pros reading Endpoints daily — and it's free.